Skip to main content
Fig. 1 | Journal of Translational Medicine

Fig. 1

From: An integrated prognosis model of pharmacogenomic gene signature and clinical information for diffuse large B-cell lymphoma patients following CHOP-like chemotherapy

Fig. 1

Integrated model analysis for OS of patients in the training dataset. Patients’ survival and disease progress status and risk score generated with integrated model were analyzed in the training set patients (GSE31312, n = 449). a The distribution plot, patients’ overall survival status and time and heatmap of the integrated model profiles. Rows represent clinical information and drug resistance probability, and columns represent patients. The grey dotted line represents the median integrated model risk score cutoff dividing patients into low- and high-score groups. Kaplan–Meier analysis for OS (b) of DLBLC patients using the integrated model in the training dataset. The ROC curves of the pharmacogenomic gene signature, clinical only model and integrated model for prediction of OS (c)

Back to article page